Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 569 matching trials from the live ClinicalTrials.gov search.
Conditions
HIV Infections, Lipodystrophy
Interventions
raltegravir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio + 1 more
Conditions
Sleep Deprivation, Nutritional Intervention
Interventions
Ketogenic Intervention, Mediterranean Intervention, Placebo, Ketone Ester
Other · Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Healthy
Interventions
Losartan potassium/Hydrochlorothiazide
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Rifapentine on Raltegravir

NCT00809718
Conditions
Healthy
Interventions
Raltegravir and rifapentine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Sinus Infection, Acute Sinusitis
Interventions
amoxicillin/clavulanate potassium, Placebo, Budesonide nasal spray
Drug
Lead sponsor
Daniel Merenstein
Other
Eligibility
18 Years to 75 Years
Enrollment
3,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease
Interventions
DASH/sodium-restricted diet (SRD)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Distal Renal Tubular Acidosis
Interventions
ADV7103, Placebo
Drug
Lead sponsor
Advicenne Pharma
Industry
Eligibility
6 Months to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 3 more
Conditions
Patients Undergoing Screening or Surveillance Colonoscopy
Interventions
PEG+E, PEG+Asc, P+MC, sulfate
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Hypertensive Disease
Interventions
Potassium control diet, Potassium gluconate diet, Potato Diet, French Fries Diet
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Lafayette, Indiana
Completed No phase listed Observational Results available

Evaluation of Micropore"s SpiraLith Absorbents

NCT02550470
Conditions
Airway Management During Operative Procedure
Interventions
Carbon Dioxide Absorbents, Micropore SpiraLith, Sevoflurane
Device · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
Not listed
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Hyperkalemia
Interventions
Blood sample drawn from a vein, Blood sample drawn from a heel stick
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 6 Months
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 2 Interventional Results available

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

NCT00490009
Conditions
Lymphoma
Interventions
Bexxar, Acetaminophen, Diphenhydramine, Potassium Iodide (KI)
Drug
Lead sponsor
Susan Knox
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Stanford, California
Completed Not applicable Interventional Results available

Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

NCT00879879
Conditions
Precancerous Condition
Interventions
losartan
Drug
Lead sponsor
University of South Florida
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Human Immunodeficiency Virus
Interventions
Raltegravir, Dolutegravir, Colonoscopy with biopsy
Drug · Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Overweight, Obesity, Aging, Menopause
Interventions
70 mL red beetroot juice, 70 mL red beetroot juice without nitrate, 70 mL placebo drink plus potassium nitrate, 70 mL placebo drink
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
40 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fort Collins, Colorado
Conditions
Type2 Diabetes, Hyperkalemia
Interventions
Spironolactone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 4 Interventional Results available

Raltegravir Intensification in HIV-infected Patients

NCT00631449
Conditions
HIV Infections
Interventions
Raltegravir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
San Francisco, California
Conditions
HIV Infections
Interventions
darunavir 800 mg, FTC 200 mg/TDF 300mg, Maraviroc, Raltegravir, Ritonavir 100 mg
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
New York, New York
Terminated Not applicable Interventional Results available

Comparing TR Band to Statseal in Conjunction With TR Band II

NCT04046952
Conditions
Arterial Occlusion, Cardiovascular Diseases, Atherosclerosis, Hematoma, Anticoagulant-induced Bleeding, Coronary Artery Disease
Interventions
Statseal with TR Band, TR band only
Device
Lead sponsor
VA Long Beach Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Long Beach, California
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
13
States / cities
San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more
Conditions
Hyperkalemia
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Huntsville, Alabama • La Jolla, California • Rancho Cucamonga, California + 14 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

NCT00802074
Conditions
Healthy
Interventions
Raltegravir, Fosamprenavir, Ritonavir
Drug
Lead sponsor
Garden State Infectious Disease Associates, PA
Other
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Voorhees Township, New Jersey
Conditions
Metabolic Health, Weight Loss, Stress, Well-Being, Psychological, Sleep, Healthy Eating
Interventions
Slimbiotic Probiotic, Placebo
Other
Lead sponsor
Slimbiotics
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Kidney Disease
Interventions
Propranolol, Losartan, Eprosartan
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California